Skip to content

Endotracheal Tube With Polyurethane Cuff and Subglottic Secretion Drainage

Influence of an Endotracheal Tube With Polyurethane Cuff and Subglottic Secretion Drainage on Ventilator-Associated Pneumonia

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00475579
Acronym
A/N
Enrollment
280
Registered
2007-05-21
Start date
2006-03-31
Completion date
2006-10-31
Last updated
2007-05-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Mechanical Ventilation

Keywords

ventilator-associated pneumonia, endotracheal tube, polyurethane cuff, polyvinyl cuff, subglottic secretion drainage

Brief summary

Patients mechanically ventilated using an endotracheal tube with a subglottic secretion drainage lumen and a polyurethane cuff may develop lower ventilator-associated pneumonia than using a conventional endotracheal tube

Detailed description

Subglottic secretions accumulated above the endotracheal cuff may progress, descending along the channels within folds of the cuff wall, to the lower respiratory tract causing VAP. Subglottic secretion drainage (SSD) appears to be effective in preventing VAP, primarily by reducing early-onset pneumonia; but it may not prevent late-onset pneumonia. We set out the hypothesis that using an endotracheal tube incorporating, besides of a subglottic secretion drainage lumen, a polyurethane cuff (which reduces channel formation and fluids leakage from the subglottic area) it should be also possible to reduce the incidence of late-onset VAP.

Interventions

PROCEDUREtube with subglottic drainage and polyurethane cuff

Sponsors

Hospital Universitario de Canarias
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 90 Years
Healthy volunteers
No

Inclusion criteria

* Patients expected to require mechanical ventilation for more than 24 hours

Exclusion criteria

* Age \<18 years, * Pregnancy, * HIV, * Blood leukocytes counts \<1000 cells/mm3, * Solid or haematological tumour, * Immunosuppressive therapy

Design outcomes

Primary

MeasureTime frame
Ventilator-associated pneumonia8 months

Secondary

MeasureTime frame
Late-onset ventilator-associated pneumonia8 months

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026